Applying the AIM concept in support of developing improved in vitro-in vivo relationships for OIPs

Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products

Volumn 9781461462965, Issue , 2013, Pages 375-400

  Mitchell, Jolyon P ^a   Copley, Mark ^b   Solomon, Derek ^c  

^a TRUDELL MEDICAL INTERNATIONAL   (Canada)

^b Copley Scientific Limited ^*  (United Kingdom)

^c Melbourn Scientific Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949178643     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6296-5_12     Document Type: Chapter

References (66)

1. Mitchell JP, Newman SP, Chan H-K (2007) In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech 8(4): article 24 at: http://www.aapspharmscitech.org/view.asp?art=pt0804110. Accessed 23 Jan 2012
2. Newman SP, Chan H-K (2008) In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med 21(1):1-8
3. Gonda I (1990) Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. Crit Rev Ther Drug Carrier Syst 7:273-313
4. Patton JS, Bukar JG, Eldon MA (2004) Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43(12):781-801
5. Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ (2003) Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 95(5):2106-2112
6. Usmani OS, Biddiscombe MF, Barnes PJ (2005) Regional lung deposition and bronchodilator response as a Function of ?2-agonist particle size. Am J Respir Crit Care Med 172(12): 1497-1504
7. Dunbar C, Mitchell JP (2005) Analysis of cascade impactor mass distributions. J Aerosol Med 18(4):439-451
8. Vincent JH (1995) The inhalation of aerosols. In: Vincent JH (ed) Aerosol science for industrial hygienists. Pergamon Press, Oxford, pp 136-155
9. Dolovich MB, Rhem R (1998) Impact of oropharyngeal deposition on inhaled dose. J Aerosol Med 11(S1):S112-S115
10. Borgström L, Olsson B, Thorsson L (2006) Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 19(4):473-483
11. Cheng YS, Zhou Y, Chen BT (1999) Particle deposition in a cast of human oral airways. Aerosol Sci Technol 31(4):286-300
12. Swift DL (1992) Apparatus and method for measuring regional distribution of therapeutic aerosols and comparing delivery systems. J Aerosol Sci 23(S1):S495-S498
13. Berg E (1995) In vitro properties of pressurized metered dose inhalers with and without spacer devices. J Aerosol Med 8(S3):S3-S11
14. Velasquez DJ, Gabrio B (1998) Metered dose inhaler aerosol deposition in a model of the human respiratory system and a comparison with clinical deposition studies. J Aerosol Med 11(S1):S23-S28
15. Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, Ortega HG (2009) Pharmacokinetic, pharmacodynamic, effi cacy, and safety data from two randomized, doubleblind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 ?g and fl uticasone propionate 250 ?g: implications for establishing bioequivalence of inhaled products. Clin Thera 31(2):370-385
16. Grgic B, Finlay WH, Burnell PKP, Heenan AF (2004) In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. J Aerosol Sci 35(8):1025-1040
17. Finlay WH (2012) New validated extrathoracic and pulmonary deposition models for infants and children. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (eds) Respiratory drug delivery-2012. Davis HealthCare International Publishing, River Grove, IL, pp 325-336
18. Golshahi L, Noga ML, Thompson RB, Finlay WH (2011) In vitro deposition measurement of inhaled micrometer-sized particles in nasal airways of children and adolescents during nose breathing. J Aerosol Sci 42(7):474-488
19. Golshahi L, Noga ML, Finlay WH (2012) Deposition of inhaled micrometer-sized particles in oropharyngeal airway replicas of children at constant fl ow rates. J Aerosol Sci 49(1):21-31
20. Rennard SI (2005) Anticholinergics in combination bronchodilator therapy in COPD. In: Spector SL (ed) Anticholinergic agents in the lower and upper airways. Dekker, New York, NY, pp 97-111
21. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, Craig TJ, Dolovich M, Drazen JM, Fagan JK, Fahy JV, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lazarus SC, Lemanske RF, Mauger E, Peters SP, Sorkness CA (2002) Signifi cant variability in response to inhaled steroids for persistent asthma. J Allergy Clin Immunol 109(3):S410-S418
22. Everard ML, Dolovich MB (2002) In vivo measurements of lung dose. In: Bisgaard H, O?Callaghan C, Smaldone GC (eds) Drug delivery to the lung. Dekker, New York, NY, pp 173-209
23. Dolovich MB (1993) Lung dose, distribution, and clinical response to therapeutic aerosols. Aerosol Sci Technol 18(3):230-240
24. American Thoracic Society (ATS) (1995) Standardization of spirometry-1994 update. Am J Respir Crit Care Med 152(3):1107-1136
25. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S (2009) Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs). AAPS PharmSciTech 10(4):1276-1285
26. Mitchell JP, Nagel MW (2003) Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med 16(4):341-377
27. Olsson B, Borgstrom L, Asking L, Bondesson E (1996) Effect of inlet throat on the correlation between measured fi ne particle dose and lung deposition. In: Dalby RN, Byron PR, Farr SJ (eds) Respiratory drug delivery-V. Interpharm Press, Buffalo Grove, IL, pp 273-282
28. Ehtezazi T, Horsfi eld MA, Barry PW, OCallaghan C (2004) Dynamic change of the upper airway during inhalation via aerosol devices. J Aerosol Med 17(4):325-334
29. Ehtezazi T, Southern KW, Allanson D, Jenkinson I, Ocallaghan C (2005) Suitability of the upper airway models obtained from MRI studies in simulating drug lung deposition from inhalers. Pharm Res 22(1):166-170
30. Swift DL (1994) The oral airway-a conduit or collector for pharmaceutical aerosols. In: Byron P, Dalby RN, Farr SJ (eds) Respiratory drug delivery IV. Interpharm Press, Buffalo Grove, IL, pp 187-195
31. COPHIT Consortium (2012) Anatomic oropharyngeal model, at: http://www.isam.org/. Visited 25 June 2012
32. McRobbie DW, Pritchard S, Quest RA (2003) Studies of the human oropharyngeal airspaces using magnetic resonance imaging. I. Validation of a three-dimensional MRI method for producing ex vivo virtual and physical casts of the oropharyngeal airways during inspiration. J Aerosol Med 16(4):401-415
33. Ilie M, Matida EA, Finlay WH (2008) Asymmetrical aerosol deposition in an idealized mouth with a DPI mouthpiece inlet. Aerosol Sci Technol 42(1):10-17
34. Zhang Y, Gilbertson K, Finlay WH (2007) In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers. J Aerosol Med 20(3):227-235
35. Stapleton KW, Guentsch E, Hoskinson MK, Finlay WH (2000) On the suitability of k- turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment. J Aerosol Sci 31(6):731-749
36. Grgic B, Finlay WH, Heenan AF (2004) Regional aerosol deposition and fl ow measurements in an idealized mouth and throat. J Aerosol Sci 35(1):21-32
37. Stocks J, Hislop AA (2002) Structure and function of the respiratory system. In: Bisgaard H, O?Callaghan C, Smaldone GC (eds) Drug delivery to the lung. Dekker, New York, NY, pp 47-104
38. Everard ML (2004) Inhaler devices in infants and children: challenges and solutions. J Aerosol Med 17(2):186-195
39. Mitchell JP, Nagel MW, Doyle C, Ali RS, Avvakoumova V, Christopher D, Quiroz J, Strickland H, Tougas T, Lyapustina S (2010) Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen Cascade Impactors (ACIs): Part 1. AAPS PharmSciTech 11(2):843-851
40. Mitchell JP, Nagel MW, Doyle C, Ali RS, Avvakoumova V, Christopher D, Quiroz J, Strickland H, Tougas T, Lyapustina S (2010) Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen Cascade Impactors (ACIs): Part 2-Investigation of bias in extra-fi ne mass fraction with AIM-HRT impactor. AAPS PharmSciTech 11(3):1115-1118
41. Chambers FE, Smurthwaite M (2012) Comparative performance evaluation of the Westech Fine Particle Dose (FPD) impactor. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (eds) Respiratory drug delivery-2012. Davis HealthCare International Publishing, River Grove, IL, pp 553-558
42. Mitchell JP, Copley M, Sizer Y, Russell T, Solomon D (2012) Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" Idealized Throat (AIT) inlet. J Aerosol Med Pulm Drug Deliv 25(4):188-197
43. Ehtezazi T, Saleem I, Shrubb I, Allanson ID, Ocallaghan C (2010) The interaction between the oropharyngeal geometry and aerosols via pressurized metered dose inhalers. Pharm Res 27(1):175-186
44. Mitchell JP, Nagel MW, Avvakoumova V, MacKay H, Ali R (2009) The abbreviated impactor measurement (AIM) concept: part 1-infl uence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (MDI)-based formulation. AAPS PharmSciTech 10(1):243-251
45. Copley M, Mitchell J, Solomon D (2011) Evaluating the Alberta throat: an innovation to support the acquisition of more clinically applicable aerosol aerodynamic particle size distribution (APSD) data in oral inhaled product (OIP) development. Inhalation 5(4):12-16
46. Roberts DL, Mitchell JP (2011) Infl uence of stage effi ciency curves on interpretation of abbreviated impactor data. Drug delivery to the lungs-22, The Aerosol Society, Edinburgh, UK, pp 177-180. Available at: http://ddl-conference.org.uk/index.php?q=previous-conferences. Visited 4 Aug 2012
47. Dolovich MB, Mitchell JP (2004) Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers. Can Respir J 11(7):489-495
48. Mitchell JP, Nagel M, Finlay B (2011) Advances in models for laboratory testing of inhalers: there?s more to it than meets the nose or mouth-The ADAM face models. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (eds) Respiratory drug delivery Europe-2011. Davis Healthcare International Publishing LLC, River Grove, IL, pp 457-461
49. European Directorate for the Quality of Medicines and Healthcare (EDQM). Preparations for inhalation: aerodynamic assessment of fine particles. (2012) Section 2.9.18-European Pharmacopeia, Council of Europe, 67075 Strasbourg, France
50. United States Pharmacopeial Convention (2012) USP 35-NF 30 Chapter 601: Aerosols, nasal sprays, metered-dose inhalers and dry powder inhalers. Rockville, MD
51. Feddah MR, Brown KF, Gipps EM, Davies NM (2000) In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: infl uence of inspiratory fl ow rates. J Pharm Pharm Sci 3(3):317-324
52. Burnell PKP, Malton A, Reavill K, Ball MHE (1998) Design, validation and initial testing of the Electronic Lung™ device. J Aerosol Sci 29(8):1011-1025
53. Hamilton M, Daniels G (2011) Assessment of early screening methodology using the Next Generation and Fast Screen Impactor systems. Drug Delivery to the Lungs-22, The Aerosol Society, Edinburgh, UK, 22:355-358. Available at: http://ddl-conference.org.uk/index.php?q=previous-conferences. Visited 4 Aug 2012
54. Miller NC (2002) Apparatus and process for aerosol size measurement at varying gas fl ow rates. US Patent 6,435,004-B1
55. Olson B, Berg E, Svensson M (2010) Comparing aerosol size distributions that penetrate mouth-throat models under realistic inhalation conditions. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM (eds) Respiratory drug delivery-2010. Davis Healthcare International Publishing, River Grove, IL, pp 225-234
56. Mitchell JP, Dolovich MB (2012) Clinically relevant test methods to establish in vitro equivalence for spacers and valved holding chambers used with pressurized metered dose inhalers (MDIs). J Aerosol Med Pulm Drug Deliv 25(4):217-242
57. Dolovich MB (2004) In my opinion: interview with the expert. Pediatr Asthma Allergy Immunol 17(4):292-300
58. Morton RW, Mitchell JP (2007) Design of facemasks for delivery of aerosol-based medication via pressurized metered dose inhaler with valved holding chamber: Key issues that affect performance. J Aerosol Med 20(S1):S29-S45
59. Finlay WH, Zuberbuhler P (1999) In vitro comparison of salbutamol hydrofl uoroalkane (Airomir) metered dose inhaler aerosols inhaled during pediatric tidal breathing from fi ve valved holding chambers. J Aerosol Med 12(4):285-291
60. Shah SA, Berlinski A, Rubin BK (2006) Force-dependent static dead space of face masks used with holding chambers. Respir Care 51(2):140-144
61. Mitchell JP, Finlay JB, Nuttall JM, Limbrick MR, Nagel MW, Avvakoumova V, MacKay H, Ali RS, Doyle CC (2011) Validation of a new model infant face with nasopharynx for the testing of valved holding chambers (VHCs) with facemask as a patient interface. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ (eds) Respiratory drug delivery-2010. Davis Healthcare International Publishing LLC, River Grove, IL, pp 777-780
62. Mitchell JP (2008) Appropriate face models for evaluating drug delivery in the laboratory: the current situation and prospects for future advances. J Aerosol Med 21(1):1-15
63. Storey-Bischoff J, Noga M, Finlay WH (2008) Deposition of micrometer-sized aerosol particles in infant nasal airway replicas. J Aerosol Sci 39(12):1055-1065
64. Newhouse MT (1998) The current laboratory determination of "Respirable Mass" is not clinically relevant. J Aerosol Med 11(S1):S122-S132
65. Labiris NR, Dolovich MB (2003) Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 5(12):588-599
66. Marple VA, Olson BA, Santhanakrishnan K, Mitchell JP, Murray SC, Hudson-Curtis BL (2004) Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aerosol Med 17(4):335-343